Enzalutamide Combo Shows No MFS Improvement in Advanced Prostate Cancer

The phase 3 ENZARAD (ANZUP 1303) trial (NCT02446444) showed no improvement in metastasis-free survival (MFS) with the addition of enzalutamide (Xtandi) to androgen deprivation therapy (ADT) and high-dose radiation among those with high-risk…